Symposium presentations最新文献

{"title":"S01.1 Identification of bacteria associated with idiopathic nongonococcal urethritis","authors":"S. Srinivasan","doi":"10.1136/SEXTRANS-2021-STI.19","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.19","url":null,"abstract":"","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130382019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S09.1 Antimicrobial Resistance Directed Therapy for Neisseria gonorrhoeae","authors":"L. Allan-Blitz","doi":"10.1136/SEXTRANS-2021-STI.42","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.42","url":null,"abstract":"","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130465716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S06.1 The healthcare experiences of transgender women living with HIV in the Buffalo City Metro Municipality","authors":"L. V. D. Merwe, A. Mavhandu-Mudzusi","doi":"10.1136/SEXTRANS-2021-STI.34","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.34","url":null,"abstract":"","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"7 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116793894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S04.4 Evidence based approaches to preventing pelvic inflammatory disease (PID) and its sequelae","authors":"P. Oakeshott","doi":"10.1136/SEXTRANS-2021-STI.31","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.31","url":null,"abstract":"There are many challenges to preventing pelvic inflammatory disease (PID). The case definition is unclear: clinically diagnosed PID may not be confirmed by laparoscopy/endometrial biopsy/imaging. Both PID and its main cause Chlamydia trachomatis infection can be asymptomatic, and often no clear pathogen is identified. Most women (>85%) with chlamydia infection do not get PID. Finally, uptake of chlamydia screening is often low, and treatment of those infected and their sexual partners can be challenging. A 2016 Cochrane review found four trials (in 21, 686 women) which examined the effect of chlamydia screening on PID: Scholes, Ostergaard, Oakeshott, Andersen. Overall, the risk of PID was lower in women in intervention than control groups: RR 0.68, 0.49 to 0.94. But in the two trials at low risk of detection bias (Oakeshott, Andersen) the RR was 0.8, 0.55 to 1.17, compatible with no effect. Thus, although detection and treatment of chlamydia infection can reduce the risk of PID in an individual woman, the size of the effect is uncertain. It is also unclear whether chlamydia screening to prevent PID reduces rates of infertility and ectopic pregnancy. Our recent ‘Test n Treat’ trial of free rapid chlamydia tests and same day treatment in 500 sexually active, ethnically diverse teenagers, highlights the problems of persuading those at risk to get screened. Despite a 6.2% prevalence of chlamydia (and 0.6% gonorrhoea), test uptake was only 13%. Interviews suggested this was due to not feeling at risk, perceptions of stigma and little knowledge of STIs. However, £5 notes can be effective incentives, and enabled us to recruit 500 participants in 3-weeks. Cost analysis suggested incentives might be cost-effective for screening some high risk groups. We eagerly await results of the French i-Predict trial of 6-monthly chlamydia screening to reduce PID incidence over 2-years in 4000 female students.","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"95 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116043566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S07.4 Tools to enhance the global STI surveillance","authors":"T. Wi","doi":"10.1136/SEXTRANS-2021-STI.36","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.36","url":null,"abstract":"Without information, you don’t have a problem. Without a problem, you can’t advocate for resources. Without resources to tackle the problem, it grows bigger. However, without information, who would know? There is a vicious cycle of limited STI surveillance and limited funding and responses, especially in resource-limited settings. Strengthened strategic information for STIs is needed to guide programming and service delivery, to rally political commitment and build a strong national investment case. National strategic information systems that incorporate STI case reporting, prevalence assessments, assessment of the etiologies of sexually transmitted infection syndromes, and monitoring for antimicrobial resistance to gonorrhoea are required. Countries with STI surveillance systems rely on STI case reporting to estimate national incidence. Routine screening, currently most feasible for syphilis, address prevalence monitoring of priority populations. Routine reporting and prevalence monitoring have limitations. STI reporting underestimates the burden of STIs as the majority are asymptomatic, limited access to care and challenges to collect verifiable data including limited diagnostics. Without diagnostics, it is difficult to count STI cases reliably. Periodic prevalence surveys using standard methods, increase confidence in trends by validating routine data with population denominators. Specific studies including prevalence studies nested within DHS, biobehavioural surveys among key populations, a meta-analysis of STI data from other sources can enhance surveillance. Tools are available to support STI surveillance. Modelling tools including Spectrum STI and the congenital syphilis estimation tool are available for national-level analysis of incidence and prevalence trends. Prevalence survey tools for pregnant women and enhanced gonorrhoea antimicrobial resistance surveillance programme protocol are available. A review of reporting tools is underway. Striking the right balance of STI surveillance activities requires resources, building reporting systems and strengthening capacity at the national level to conduct and improve routine surveillance, while simultaneously investing in prevalence surveys and special studies.","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133023057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S02.1 Antimicrobial resistance and extragenital STIs – pharmacokinetic considerations","authors":"F. Kong","doi":"10.1136/SEXTRANS-2021-STI.23","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.23","url":null,"abstract":"","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134156222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S10.2 Cervical cancer screening: benefits and challenges of HPV self-sampling in Mozambique","authors":"N. Osman","doi":"10.1136/SEXTRANS-2021-STI.46","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.46","url":null,"abstract":"","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121083793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S10.3 Point-of-care HPV testing and treatment for cervical cancer screening and elimination in Papua New Guinea","authors":"A. Vallely","doi":"10.1136/SEXTRANS-2021-STI.47","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.47","url":null,"abstract":"Papua New Guinea (PNG) has among the highest estimated burdens of cervical cancer globally, but lacks national programs for cervical screening or human papillomavirus (HPV) vaccination. Following the disappointing performance of visual inspection of the cervix with acetic acid (VIA) for cervical screening in this setting, we evaluated a novel same-day ‘test-and-treat’ screening model based on point-of-care HPV-DNA testing of self-collected vaginal specimens followed by same-day thermal ablation of the cervix. Self-collected specimens tested at point-of-care on the GeneXpert platform (Xpert HPV; Cepheid, Sunnyvale, CA) had comparable performance to laboratory-based assays both for the detection of high-risk oncogenic HPV types and for detection of underlying pre-cancer and cancer. This strategy was highly acceptable among women and health care workers; highly cost-effective compared to screening based on VIA or Pap test cytology; and with suitable training and support, feasible to implement in routine primary care facilities in this setting. We further showed that if 70% of women aged 30–54 years were screened twice in their lifetime as recommended by WHO, this point-of-care ‘test and treat’ model could reduce both cervical cancer incidence and mortality in PNG by more than 50%. This approach represents a promising new model for cervical screening in PNG and other high-burden, low-income countries embarking on a path towards cervical cancer elimination.","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122689630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S03.4 M. genitalium: Is it time for surveillance?","authors":"L. Manhart","doi":"10.1136/SEXTRANS-2021-STI.29","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.29","url":null,"abstract":"","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128353649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S07.2 Using surveillance data to detect HIV clusters and outbreaks and respond to address gaps in prevention","authors":"A. Oster","doi":"10.1136/SEXTRANS-2021-STI.35","DOIUrl":"https://doi.org/10.1136/SEXTRANS-2021-STI.35","url":null,"abstract":"","PeriodicalId":301606,"journal":{"name":"Symposium presentations","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116911764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}